SINGH, Nishita, Nima KASHANI, Manon KAPPELHOF, Petra CIMFLOVÁ, Johanna OSPEL, Rosalie MCDONOUGH, Bijoy MENON, Michael CHEN, Jens FIEHLER, Noboyuki SAKAI and Mayank GOYAL. Willingness to randomize primary medium vessel occlusions for endovascular treatment. JOURNAL OF NEURORADIOLOGY. ISSY: MASSON EDITEUR, 2022, vol. 49, No 2, p. 157-163. ISSN 0150-9861. Available from: https://dx.doi.org/10.1016/j.neurad.2021.08.001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Willingness to randomize primary medium vessel occlusions for endovascular treatment
Authors SINGH, Nishita, Nima KASHANI, Manon KAPPELHOF, Petra CIMFLOVÁ (203 Czech Republic, belonging to the institution), Johanna OSPEL, Rosalie MCDONOUGH, Bijoy MENON, Michael CHEN, Jens FIEHLER, Noboyuki SAKAI and Mayank GOYAL (guarantor).
Edition JOURNAL OF NEURORADIOLOGY, ISSY, MASSON EDITEUR, 2022, 0150-9861.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30224 Radiology, nuclear medicine and medical imaging
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.500
RIV identification code RIV/00216224:14110/22:00128429
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.neurad.2021.08.001
UT WoS 000775411600006
Keywords in English Acute ischemic stroke; Medium vessel occlusion; Distal occlusion; Endovascular therapy
Tags 14110119, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2023 10:29.
Abstract
Background and purpose: Patients with acute ischemic stroke due to medium vessel occlusion (MeVO) make up a substantial part of the acute stroke population, though guidelines currently do not recommend endovascular treatment (EVT) for them. A growing body of evidence suggests that EVT is effective in MeVOs, including observational data but no randomized studies. We aimed to explore willingness of physicians worldwide to randomize MeVO stroke patients into a hypothetical trial comparing EVT in addition to best medical management versus best medical management only. Methods: In an international cross-sectional survey among stroke physicians, participants were presented with 4 cases of primary MeVOs (6 scenarios each). Each subsequent scenario changed one key patient characteristic compared to the previous one, and asked survey participants whether they would be willing to randomize the described patient. Overall, physician- and scenario-specific decision rates were calculated. Multivariable logistic regression with clustering by respondent was performed to assess factors influencing the decision to randomize. Results: Overall, 366 participants (56 women) from 44 countries provided 8784 answers to 24 MeVO case scenarios. The majority of responses (78.3%) were in favor of randomizing. Most physicians were willing to accept patients transferred for EVT from a primary center (82%) and the majority of these (76.5%) were willing to randomize these patients after transfer. Patient age > 65 years, A3 occlusion, small core volume, and patient intravenous alteplase eligibility significantly influenced the physician's decision to randomize (adjOR 1.24, 95%CI 1.13-1.36; adjOR 1.17, 95%CI 1.01-1.34; adjOR 0.98, 95%CI 0.97-0.99 and adjOR 1.38, 95%CI 1.21 -1.57, respectively). Conclusions: Most physicians in this survey were willing to randomize acute MeVO stroke patients irrespective of patient characteristics into a trial comparing EVT in addition to best medical management versus best medical management only, suggesting there is clinical equipoise.
PrintDisplayed: 31/7/2024 13:30